- This article examines whether DexCom is fairly priced at current levels by focusing on what investors receive for the price they pay.
- DexCom's share price recently closed at US$62.22, reflecting returns of a 5.9% decline over 7 days, a 14.9% decline over 30 days, a 6.5% decline year to date, a 0.7% change over 1 year, a 44.7% decline over 3 years and a 34.2% decline over 5 years, which provides important context for any valuation view.
- Recent news coverage has centered on DexCom's role in continuous glucose monitoring and how investors are reassessing growth expectations and risk appetite in this space. Headlines have highlighted how sentiment can shift quickly for medical technology companies, which helps frame the recent share price moves regardless of your stance on the company.
- DexCom currently has a valuation score of 3 out of 6. The rest of this article will break down how different valuation methods assess the stock and then conclude by looking at a more detailed way to think about what that score means for you.
Approach 1: DexCom Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using a required return. It is essentially asking what tomorrow’s cash is worth in today’s dollars.
For DexCom, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s last twelve month Free Cash Flow stands at about US$1.08b. Analysts and extrapolations point to projected Free Cash Flow of US$1.66b by 2030, with a detailed path of estimates and extensions between 2026 and 2035 based on the cash flow projections data provided.
Rolling all these yearly cash flows together and discounting them produces an estimated intrinsic value of US$63.57 per share, compared with the recent share price of US$62.22. That implies the stock is about 2.1% below the model’s estimate, which is a very small gap and suggests the market price and this DCF view are closely aligned.
Result: ABOUT RIGHT
DexCom is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Approach 2: DexCom Price vs Earnings
For profitable companies, the P/E ratio is a useful way to think about value, because it ties the share price directly to the earnings that support it. You are essentially asking how many dollars you are paying for each dollar of current earnings.
What counts as a reasonable P/E depends on how the market views a company’s growth potential and risk. Higher growth expectations or lower perceived risk often justify a higher multiple, while slower growth or higher uncertainty usually align with a lower multiple.
DexCom currently trades on a P/E of 28.63x, compared with the Medical Equipment industry average of about 27.43x and a peer average of 23.19x. Simply Wall St’s Fair Ratio for DexCom is 29.41x, which is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margin, market cap and specific risks.
This Fair Ratio can be more helpful than a simple comparison with peers or the industry because it adjusts for DexCom’s own profile rather than treating all companies as if they were the same. With the current P/E slightly below the Fair Ratio, the share price and this multiple based view appear closely aligned.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your DexCom Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your short, plain English story about DexCom that ties your view of its products, competition, risks and opportunities to a set of numbers, a financial forecast and ultimately a fair value that you can compare with today’s share price.
On Simply Wall St’s Community page, Narratives are available as an easy tool that let you set assumptions for future revenue, earnings and margins, then see how those assumptions translate into a fair value that updates automatically when new news, earnings or guidance arrives.
That link between story and numbers can help you decide what to do when the market price and your Narrative fair value move apart. For example, your Narrative may imply DexCom is worth closer to the more bullish US$112 per share view or nearer to the more cautious US$68 per share view, while the consensus fair value on the platform currently sits around US$86.12.
Do you think there's more to the story for DexCom? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com